United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2019_register
executive
2019-02-07
article
Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments
Notices
D09002ee1bdb7beac
D09002ee1bdb7bf7e
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
Food and Drug Administration
originator
org
United States Government Agency or Subagency
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
84 FR 2530
https://www.govinfo.gov/app/details/FR-2019-02-07/2019-01481
2019-01481
fr07fe19-68
4164-01-P
Docket No. FDA-2019-N-0125
https://www.govinfo.gov/app/details/FR-2019-02-07/2019-01481
https://www.govinfo.gov/content/pkg/FR-2019-02-07/html/2019-01481.htm
https://www.govinfo.gov/content/pkg/FR-2019-02-07/pdf/2019-01481.pdf
3 p.
2530
2532
84 FR 2530
Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments; Federal Register Vol. 84, Issue
NOTICE
2019-01481
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
2019-02-26
Docket No. FDA-2019-N-0125
4164-01-P
2019-01481
Notice; establishment of a public docket; request for comments.
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
The meeting will be held on February 26, 2019, from 12:30 p.m. to 5 p.m.
Lauren D. Tesh, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301- 796-9001, Fax: 301-847-8533, email: ODAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the FDA's website at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.
Meetings:
Oncologic Drugs Advisory Committee
,
fdaoma@fda.hhs.gov
ODAC@fda.hhs.gov
https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm
https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm
https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm
https://www.fda.gov/AdvisoryCommittees/default.htm
https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf
https://www.regulations.gov
Federal Register
Vol. 84, no. 26
Office of the Federal Register, National Archives and Records Administration
2019-02-07
continuing
daily
deposited
born digital
288 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2019-02-07
P0b002ee19f2d7fb7
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr07fe19
https://www.govinfo.gov/app/details/FR-2019-02-07
https://www.govinfo.gov/content/pkg/FR-2019-02-07/pdf/FR-2019-02-07.pdf
https://www.govinfo.gov/content/pkg/FR-2019-02-07/xml/FR-2019-02-07.xml
fdlp
2427
2704
DGPO
2019-02-07
2023-04-28
FR-2019-02-07
machine generated
eng
FR
FR-2019-02-07
84
26